Technical Summary on Pharma Stocks -- Research on Pacira Pharma, Ventrus Biosciences, Teva Pharma, and Novo Nordisk Editor Note: For more information about this release, please scroll to bottom.
LONDON, May 19, 2014 /PRNewswire/ --
The trading session on Friday, May 16, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,491.31, up 0.27% and the NASDAQ Composite closed at 4,090.59, up 0.52%. The S&P 500 finished the day 0.37% higher at 1,877.86. During the Friday's session, nine out of ten sectors ended on a higher note. The S&P 500 Health Care Sector Index ended the day at 671.93, up 0.35%, with the index advancing 2.03% in the last one month. Investor-Edge has initiated coverage on the following equities: Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Ventrus Biosciences Inc. (NASDAQ: VTUS), Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Novo Nordisk (NYSE: NVO). Free technical research on PCRX, VTUS, TEVA and NVO can be downloaded upon signing up at:
On Friday, shares in Pacira Pharmaceuticals Inc. fluctuated between $73.18 and $75.59 before ending the session 0.13% lower at $75.11. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.53 million shares. Pacira Pharmaceuticals Inc.'s shares have fallen by 1.50% in the previous three trading sessions, while the stock has surged 13.72% in the last one month and 30.65% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $70.11 and $57.20, respectively. Moreover, shares of Pacira Pharmaceuticals Inc. have a Relative Strength Index (RSI) of 56.60. Sign up today to read free research on PCRX at:
On Friday, shares in Ventrus Biosciences Inc. edged 0.95% higher, to close the day at $1.06. The stock recorded a trading volume of 0.14 million shares, much below its three months average volume of 0.53 million shares. The stock oscillated between $1.05 and $1.08 during the session. Over the last three trading sessions, Ventrus Biosciences Inc.'s shares have gained 2.91%. However, the stock has lost 1.85% the past one month and 72.25% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $2.51 is greater than its 50-day moving average of $1.19. Additionally, Ventrus Biosciences Inc.'s stock has an RSI of 43.18. Sign up today to read free research on VTUS at:
On Friday, shares in Teva Pharmaceutical Industries Ltd recorded a trading volume of 3.44 million shares, lower than its three months average volume of 6.85 million shares. The stock ended the day at $49.81, which was 0.52% below its previous day's closing of $50.07, and registered an intraday range of $49.28 and $50.00. Although Teva Pharmaceutical Industries Ltd's stock has fallen by 2.71% in the previous three trading sessions and 2.05% in the last one month, it has gained 24.28% on YTD basis. The stock is trading above its 200-day moving average of $43.16, while the 200-day moving average is below Teva Pharmaceutical Industries Ltd's 50-day moving average of $50.26. Furthermore, shares of the company have an RSI of 48.36. Sign up today to read free research on TEVA at:
Novo Nordisk's stock finished the Friday's session 0.12% lower at $42.41. A total of 1.10 million shares were traded, which was below its three months average volume of 1.50 million shares. The stock vacillated between $42.16 and $42.95 during the session. Over the last one month and over the previous three months, Novo Nordisk's shares have fallen by 3.94% and 4.33%, respectively. However, from the beginning of 2014, the company's stock has gained an upside of 14.77%. The company's stock is trading above its 200-day moving average. Moreover, Novo Nordisk's 50-day moving average of $44.54 is above its 200-day moving average of $38.58. The company's stock has an RSI of 36.86. Sign up today to read free research on NVO at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.